221 related articles for article (PubMed ID: 19744744)
41. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
[TBL] [Abstract][Full Text] [Related]
42. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
43. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
44. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.
Johnston FM; Tan MC; Tan BR; Porembka MR; Brunt EM; Linehan DC; Simon PO; Plambeck-Suess S; Eberlein TJ; Hellstrom KE; Hellstrom I; Hawkins WG; Goedegebuure P
Clin Cancer Res; 2009 Nov; 15(21):6511-8. PubMed ID: 19843662
[TBL] [Abstract][Full Text] [Related]
45. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers.
Brinkmann U; Webber K; Di Carlo A; Beers R; Chowdhury P; Chang K; Chaudhary V; Gallo M; Pastan I
Int J Cancer; 1997 May; 71(4):638-44. PubMed ID: 9178820
[TBL] [Abstract][Full Text] [Related]
46. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
Aktas B; Kasimir-Bauer S; Wimberger P; Kimmig R; Heubner M
Anticancer Res; 2013 Jan; 33(1):329-36. PubMed ID: 23267165
[TBL] [Abstract][Full Text] [Related]
47. Localization of mesothelin in epithelial ovarian cancer.
Hassan R; Kreitman RJ; Pastan I; Willingham MC
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):243-7. PubMed ID: 16082249
[TBL] [Abstract][Full Text] [Related]
48. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Lindenberg L; Thomas A; Adler S; Mena E; Kurdziel K; Maltzman J; Wallin B; Hoffman K; Pastan I; Paik CH; Choyke P; Hassan R
Oncotarget; 2015 Feb; 6(6):4496-504. PubMed ID: 25756664
[TBL] [Abstract][Full Text] [Related]
49. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
50. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
52. Mesothelin: a new target for immunotherapy.
Hassan R; Bera T; Pastan I
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3937-42. PubMed ID: 15217923
[TBL] [Abstract][Full Text] [Related]
53. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
[TBL] [Abstract][Full Text] [Related]
54. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
55. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
56. Control of human mesothelin-expressing tumors by DNA vaccines.
Chang CL; Wu TC; Hung CF
Gene Ther; 2007 Aug; 14(16):1189-98. PubMed ID: 17581599
[TBL] [Abstract][Full Text] [Related]
57. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
59. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
60. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
